MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and ‘wild type’ melanomas

Targeted therapy has become a cornerstone for the treatment of melanoma patients. Targeting NRAS function is particularly challenging. To date, only single MEK inhibitor treatment was able to show minimal clinical efficacy. The discovery that co-targeting of MEK and CDK4,6 has antitumor activity cre...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Posch, Christian, Sanlorenzo, Martina, Ma, Jeffrey, Kim, Sarasa T., Zekhtser, Mitchell, Ortiz-Urda, Susana
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2018
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201855/
https://ncbi.nlm.nih.gov/pubmed/30405888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26204
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky